R&D

Sartorius Stedim Biotech, a global biotechnology company focused on accelerating scientific breakthroughs based in Germany, has announced the opening of its new innovation facility in Massachusetts, US.

A new 63,000-square-ft facility opened in Massachusetts earlier this month with the aims of fostering collaboration and more advances in scientific development using real-life bioprocess workflows. Other goals also include demonstrating the latest technology from Sartorius to external innovation partners and encouraging learning on-site with customers.

Services offered will include the use of R&D laboratories in addition to the use of expert teams for process and development and optimisation and validation services. The Center for Bioprocess Innovation aims to accommodate up to 120 internal and external bioprocessing experts, according to the press release.

René Fáber, CEO of Sartorius Stedim Biotech stated, “Cell and gene therapies and other novel treatments offer promising solutions for patients with previously incurable diseases. However, these modalities are still in their infancy and often require the development of new manufacturing processes, in order to become more efficient and less costly. This cutting-edge innovation centre enables us to leverage our bioprocessing tools and workflows expertise, ultimately accelerating and simplifying our customers’ path to clinical trials.”

Future-facing plans include the addition of two multi-modality suites in 2025 to allow client projects to extend into the first stage of clinical production, which will use Sartorius equipment and workflows; expanding the solutions offered to emphasise the development of novel manufacturing process for next-generation therapeutics.